- Home
- SCTX vs KIO Comparison
SCTX vs KIO Comparison
Compare SCTX & KIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SCTX | KIO |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 536.5M | 455.8M |
| IPO Year | 2026 | 2011 |
Fundamental Metrics
Financial Performance| Metric | SCTX | KIO |
|---|---|---|
| Price | $15.56 | $9.74 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $57.00 | N/A |
| AVG Volume (30 Days) | ★ 415.3K | 301.8K |
| Earning Date | 11-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.50 | $9.77 |
| 52 Week High | $39.60 | $12.18 |
Technical Indicators
Market Signals| Indicator | SCTX | KIO |
|---|---|---|
| Relative Strength Index (RSI) | 34.14 | 28.14 |
| Support Level | $13.50 | N/A |
| Resistance Level | $22.07 | $11.22 |
| Average True Range (ATR) | 2.40 | 0.12 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 7.62 | 6.62 |
Price Performance
Historical ComparisonAbout SCTX Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
About KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. The Fund's main objective is to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in a portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.